K
Knight Therapeutics Inc
TSX:GUD
Knight Therapeutics Inc
TSX:GUD
Price:
7.08
CAD
-0.42%
Market Closed
Market Cap:
CA$699m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
CA |
|
R
|
Roper Technologies Inc
F:ROP
|
US |
|
Green International Holdings Ltd
HKEX:2700
|
HK |
|
Leoni AG
XETRA:LEO
|
DE |
|
Tangrenshen Group Co Ltd
SZSE:002567
|
CN |
|
E
|
Ecomate Holdings Bhd
KLSE:ECOMATE
|
MY |
|
Covivio Hotels SCA
PAR:COVH
|
FR |
|
F
|
Fujian South Highway Machinery Co Ltd
SSE:603280
|
CN |
|
T
|
Tecnotree Oyj
OMXH:TEM1V
|
FI |
|
Emperor Watch & Jewellery Ltd
HKEX:887
|
HK |
|
Amiyaki Tei Co Ltd
TSE:2753
|
JP |
|
SMCP SA
PAR:SMCP
|
FR |
|
Impact Healthcare REIT PLC
LSE:IHR
|
UK |
|
U
|
Umm Al Qura Cement Company SJSC
SAU:3005
|
SA |
|
Shoppers Stop Ltd
NSE:SHOPERSTOP
|
IN |
|
NGL Energy Partners LP
NYSE:NGL
|
US |
|
Hangzhou Zhongya Machinery Co Ltd
SZSE:300512
|
CN |
|
Green Dot Corp
NYSE:GDOT
|
US |
|
A
|
Atrem SA
WSE:ATR
|
PL |
|
S
|
Shakey's Pizza Asia Ventures Inc
XPHS:PIZZA
|
PH |
|
Y
|
Y2 Solution Co Ltd
KRX:011690
|
KR |
Multiples-Based Value
The Multiples-Based Value of one GUD stock under the Base Case scenario is hidden CAD. Compared to the current market price of 7.08 CAD, Knight Therapeutics Inc is hidden .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GUD Multiples-Based Value
LOCKED
Multiples Across Competitors
GUD Competitors Multiples
Knight Therapeutics Inc Competitors
Knight Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
K
|
Knight Therapeutics Inc
TSX:GUD
|
702.3m CAD | 1.6 | -130.7 | 10.5 | 126 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.4 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
